A review of the pharmacology and clinical efficacy of brivaracetam

Pavel Klein,1 Anyzeila Diaz,2 Teresa Gasalla,3 John Whitesides4 1Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA; 2Neurology Patient Value Unit, UCB Pharma, Smyrna, GA, USA; 3Neurology Patient Value Unit, UCB Pharma, Monheim am Rhein, Germany; 4Asset Development, UCB Pharma, Raleigh, NC, U...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Klein P, Diaz A, Gasalla T, Whitesides J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Brivaracetam efficacy epilepsy focal seizures pharmacokinetics tolerability Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/0ead5ee8de944984aaae69016908159d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0ead5ee8de944984aaae69016908159d
record_format	dspace
spelling	oai:doaj.org-article:0ead5ee8de944984aaae69016908159d2021-12-02T06:17:37ZA review of the pharmacology and clinical efficacy of brivaracetam1179-1438https://doaj.org/article/0ead5ee8de944984aaae69016908159d2018-01-01T00:00:00Zhttps://www.dovepress.com/a-review-of-the-pharmacology-and-clinical-efficacy-of-brivaracetam-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Pavel Klein,1 Anyzeila Diaz,2 Teresa Gasalla,3 John Whitesides4 1Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA; 2Neurology Patient Value Unit, UCB Pharma, Smyrna, GA, USA; 3Neurology Patient Value Unit, UCB Pharma, Monheim am Rhein, Germany; 4Asset Development, UCB Pharma, Raleigh, NC, USA Abstract: Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive treatment of focal (partial-onset) seizures in adults. BRV is a selective, high-affinity ligand for synaptic vesicle 2A (SV2A) with 15- to 30-fold higher affinity than levetiracetam, the first AED acting on SV2A. It has high lipid solubility and rapid brain penetration, with engagement of the target molecule, SV2A, within minutes of administration. BRV has potent broad-spectrum antiepileptic activity in animal models. Phase I studies indicated BRV was well tolerated and showed a favorable pharmacokinetic profile over a wide dose range following single (10–1,000 mg) and multiple (200–800 mg/day) oral dosing. Three pivotal Phase III studies have demonstrated promising efficacy and a good safety and tolerability profile across doses of 50–200 mg/day in the adjunctive treatment of refractory focal seizures. Long-term data indicate that the response to BRV is sustained, with good tolerability and retention rate. BRV is highly effective in patients experiencing secondarily generalized tonic–clonic seizures. Safety data to date suggest a favorable psychiatric adverse effect profile in controlled studies, although limited postmarketing data are available. BRV is easy to use, with no titration and little drug–drug interaction. It can be initiated at target dose with no titration. Efficacy is seen on day 1 of oral use in a significant percentage of patients. Intravenous administration in a 2-minute bolus and 15-minute infusion is well tolerated. Here, we review the pharmacology, pharmacokinetics, and clinical data of BRV. Keywords: brivaracetam, efficacy, epilepsy, focal seizures, pharmacokinetics, tolerabilityKlein PDiaz AGasalla TWhitesides JDove Medical PressarticleBrivaracetamefficacyepilepsyfocal seizurespharmacokineticstolerabilityTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 10, Pp 1-22 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Brivaracetam efficacy epilepsy focal seizures pharmacokinetics tolerability Therapeutics. Pharmacology RM1-950
spellingShingle	Brivaracetam efficacy epilepsy focal seizures pharmacokinetics tolerability Therapeutics. Pharmacology RM1-950 Klein P Diaz A Gasalla T Whitesides J A review of the pharmacology and clinical efficacy of brivaracetam
description	Pavel Klein,1 Anyzeila Diaz,2 Teresa Gasalla,3 John Whitesides4 1Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA; 2Neurology Patient Value Unit, UCB Pharma, Smyrna, GA, USA; 3Neurology Patient Value Unit, UCB Pharma, Monheim am Rhein, Germany; 4Asset Development, UCB Pharma, Raleigh, NC, USA Abstract: Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive treatment of focal (partial-onset) seizures in adults. BRV is a selective, high-affinity ligand for synaptic vesicle 2A (SV2A) with 15- to 30-fold higher affinity than levetiracetam, the first AED acting on SV2A. It has high lipid solubility and rapid brain penetration, with engagement of the target molecule, SV2A, within minutes of administration. BRV has potent broad-spectrum antiepileptic activity in animal models. Phase I studies indicated BRV was well tolerated and showed a favorable pharmacokinetic profile over a wide dose range following single (10–1,000 mg) and multiple (200–800 mg/day) oral dosing. Three pivotal Phase III studies have demonstrated promising efficacy and a good safety and tolerability profile across doses of 50–200 mg/day in the adjunctive treatment of refractory focal seizures. Long-term data indicate that the response to BRV is sustained, with good tolerability and retention rate. BRV is highly effective in patients experiencing secondarily generalized tonic–clonic seizures. Safety data to date suggest a favorable psychiatric adverse effect profile in controlled studies, although limited postmarketing data are available. BRV is easy to use, with no titration and little drug–drug interaction. It can be initiated at target dose with no titration. Efficacy is seen on day 1 of oral use in a significant percentage of patients. Intravenous administration in a 2-minute bolus and 15-minute infusion is well tolerated. Here, we review the pharmacology, pharmacokinetics, and clinical data of BRV. Keywords: brivaracetam, efficacy, epilepsy, focal seizures, pharmacokinetics, tolerability
format	article
author	Klein P Diaz A Gasalla T Whitesides J
author_facet	Klein P Diaz A Gasalla T Whitesides J
author_sort	Klein P
title	A review of the pharmacology and clinical efficacy of brivaracetam
title_short	A review of the pharmacology and clinical efficacy of brivaracetam
title_full	A review of the pharmacology and clinical efficacy of brivaracetam
title_fullStr	A review of the pharmacology and clinical efficacy of brivaracetam
title_full_unstemmed	A review of the pharmacology and clinical efficacy of brivaracetam
title_sort	review of the pharmacology and clinical efficacy of brivaracetam
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/0ead5ee8de944984aaae69016908159d
work_keys_str_mv	AT kleinp areviewofthepharmacologyandclinicalefficacyofbrivaracetam AT diaza areviewofthepharmacologyandclinicalefficacyofbrivaracetam AT gasallat areviewofthepharmacologyandclinicalefficacyofbrivaracetam AT whitesidesj areviewofthepharmacologyandclinicalefficacyofbrivaracetam AT kleinp reviewofthepharmacologyandclinicalefficacyofbrivaracetam AT diaza reviewofthepharmacologyandclinicalefficacyofbrivaracetam AT gasallat reviewofthepharmacologyandclinicalefficacyofbrivaracetam AT whitesidesj reviewofthepharmacologyandclinicalefficacyofbrivaracetam
_version_	1718399976439021568

A review of the pharmacology and clinical efficacy of brivaracetam

Ejemplares similares